FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5ay

KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibre

Güncel ima edilen olasılık

Evet 98%

Piyasa kalitesi

44 / 100

Düşük kalite

24s Hacim

₺0

Likidite

₺49,7 B

Düşük likidite

Alis / Satis

80.0% / 86.0%

Spread

6.0 pt

Geniş spread

Piyasa verileri

24 dakika önce guncellendi

17 Haz 26 21:001 Oca 27 4:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Yes98%

Tutar (USDT)

Kurallar

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Hacim trendi

$812

3 Tem10g veri26 Tem

İlgili Piyasalar

Hantavirus pandemic in 2026?

₺4,9 Mn

Evet: 3%

POLYMARKET

# of views of MrBeast video day 3?

₺696,6 B

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

₺264,3 B

Evet: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

₺62,7 B

Above 20k: 34%

KALSHI

Bu konularda aktif

BitcoinBTC$63,323.29-2.93%

EthereumETH$1,875.31-4.53%

SolanaSOL$73.17-4.32%

DogecoinDOGE$0.07-3.71%

XRPXRP$1.05-4.89%

BNBBNB$565.51-1.15%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

FDA decision: Brepocitinib by Priovant Therapeutics (in 2026)

Health & MedicineOne-Off5ay

KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiKabaca kalibre

Güncel ima edilen olasılık

Evet 98%

Piyasa kalitesi

44 / 100

Düşük kalite

24s Hacim

₺0

Likidite

₺49,7 B

Düşük likidite

Alis / Satis

80.0% / 86.0%

Spread

6.0 pt

Geniş spread

Piyasa verileri

24 dakika önce guncellendi

17 Haz 26 21:001 Oca 27 4:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Yes98%

Tutar (USDT)

Kurallar

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.

Hacim trendi

$812

3 Tem10g veri26 Tem

İlgili Piyasalar

Hantavirus pandemic in 2026?

₺4,9 Mn

Evet: 3%

POLYMARKET

# of views of MrBeast video day 3?

₺696,6 B

26-27M: 93%

POLYMARKET

Ebola pandemic in 2026?

₺264,3 B

Evet: 3%

POLYMARKET

Measles cases in 2026?

Pandemic in 2026?

Cyclosporiasis cases reported in the US in 2026?

₺62,7 B

Above 20k: 34%

KALSHI

Bu konularda aktif

BitcoinBTC$63,323.29-2.93%

EthereumETH$1,875.31-4.53%

SolanaSOL$73.17-4.32%

DogecoinDOGE$0.07-3.71%

XRPXRP$1.05-4.89%

BNBBNB$565.51-1.15%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.